Once CHD is diagnosed, patients should be evaluated every 6–12 months for progression with TTE, NT-pro-BNP, chromogranin A, and urinary 5-HIAA levels to assess for valvular disease, heart failure, and recurrence or worsening of carcinoid malignancy [2, 11]. Here, CHGA is linked to heart failure.